Payment overview · 2025
General Payments
$385.29
14 reported records · 6 companies
Healthcare provider profile · identity verified
Shu May Lee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DALY CITY, CA · NPI 1689614992
Verified facts
What the public records show
CMS Open Payments records show Shu May Lee, M.D. received $385.29 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 54.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $211.45 | 54.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.66 | 14.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.20 | 11.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.49 | 8.9% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.14 | 5.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.35 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $385.29 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $158.61 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $134.93 | 3 | 2025 |
Source payment records
|
|||||
| ANDEXXA Normalized: andexxa |
Biological | AstraZeneca Pharmaceuticals LP | $82.09 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.66 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.66 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.49 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 292 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
292 | 90 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
292 | 90 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1209 | 366 |
| Amlodipine Besylate | Amlodipine Besylate | 959 | 274 |
| Atorvastatin Calcium | Atorvastatin Calcium | 736 | 205 |
| Metformin Hcl | Metformin Hcl | 455 | 145 |
| Tamsulosin Hcl | Tamsulosin Hcl | 407 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 110 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 355 | 98 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 347 | 108 |
| Valsartan | Valsartan | 343 | 102 |
| Famotidine | Famotidine | 298 | 92 |
| Jardiance | Empagliflozin | 292 | 90 |
| Metformin Hcl Er | Metformin Hcl | 291 | 91 |
| Alendronate Sodium | Alendronate Sodium | 255 | 80 |
| Losartan Potassium | Losartan Potassium | 240 | 71 |
| Allopurinol | Allopurinol | 211 | 60 |
| Diclofenac Sodium | Diclofenac Sodium | 204 | 106 |
| Clopidogrel | Clopidogrel Bisulfate | 192 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 164 | 49 |
| Finasteride | Finasteride | 161 | 49 |
| Ezetimibe | Ezetimibe | 150 | 52 |
| Febuxostat | Febuxostat | 139 | 46 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 124 | 61 |
| Irbesartan | Irbesartan | 122 | 38 |
| Carvedilol | Carvedilol | 114 | 36 |
| Atenolol | Atenolol | 104 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 28 |
| Januvia | Sitagliptin Phosphate | 96 | 31 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 85 | 22 |
| Eliquis | Apixaban | 81 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 25 |
| Baclofen | Baclofen | 75 | 24 |
| Gabapentin | Gabapentin | 70 | 25 |
| Lisinopril | Lisinopril | 70 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 62 |
| Risedronate Sodium | Risedronate Sodium | 69 | 22 |
| Celecoxib | Celecoxib | 66 | 21 |
| Hydrocortisone | Hydrocortisone | 66 | 29 |
| Furosemide | Furosemide | 63 | 21 |
| Meclizine Hcl | Meclizine Hcl | 63 | 31 |
| Repaglinide | Repaglinide | 62 | 20 |
| Donepezil Hcl | Donepezil Hcl | 61 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 59 | 19 |
| Fluocinonide | Fluocinonide | 58 | 31 |
| Montelukast Sodium | Montelukast Sodium | 57 | 15 |
| Ozempic | Semaglutide | 55 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 54 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 15 |
| Omeprazole | Omeprazole | 54 | 18 |
| Ciclopirox | Ciclopirox | 52 | 24 |
| Lorazepam | Lorazepam | 52 | 17 |
| Tradjenta | Linagliptin | 52 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 48 | 11 |
| Lithium Carbonate | Lithium Carbonate | 48 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 46 | 20 |
| Spironolactone | Spironolactone | 46 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 14 |
| Xarelto | Rivaroxaban | 43 | 11 |
| Chlorthalidone | Chlorthalidone | 42 | 18 |
| Ketoconazole | Ketoconazole | 42 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 15 |
| Levofloxacin | Levofloxacin | 41 | 39 |
| Vascepa | Icosapent Ethyl | 40 | 11 |
| Cephalexin | Cephalexin | 39 | 36 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 36 | 18 |
| Dutasteride | Dutasteride | 36 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Pregabalin | Pregabalin | 36 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 19 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | 12 |
| Nitroglycerin | Nitroglycerin | 34 | 24 |
| Promethazine Hcl | Promethazine Hcl | 34 | 22 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 13 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 30 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | 14 |
| Azithromycin | Azithromycin | 26 | 24 |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Entecavir | Entecavir | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Erythromycin | Erythromycin Base | 16 | 13 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Prednisone | Prednisone | 16 | 13 |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Clozapine | Clozapine | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $385.29 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ANDEXXA, BREZTRI, CREON, JARDIANCE, MOUNJARO, Ozempic, QULIPTA, Rybelsus, UBRELVY, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error